ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN

So far, there is no effective treatment for a number of socially significant bacterial and fungal diseases. β-(1→3) glucans are polysaccharides consisting of glucose units linked together with β-(1→3)- glycoside bonds. They are principal components of the fungal cell wall including such dangerous no...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	E. G. Bogomolova, O. A. Dodrovolskaya, E. A. Fedorova, A. M. Kondrashkina, N. N. Kolmakov, S. A. Ishchuk, I. V. Dukhovlinov, A. S. Simbirtsev
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2017
Materias:	conjugate vaccines recombinant crm197 antigenic activity balb/c mice Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/f8febc2e283845ccb8de097f0d48d2b1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f8febc2e283845ccb8de097f0d48d2b1
record_format	dspace
spelling	oai:doaj.org-article:f8febc2e283845ccb8de097f0d48d2b12021-11-18T08:03:46ZANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN1563-06252313-741X10.15789/1563-0625-2017-2-157-164https://doaj.org/article/f8febc2e283845ccb8de097f0d48d2b12017-05-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1218https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XSo far, there is no effective treatment for a number of socially significant bacterial and fungal diseases. β-(1→3) glucans are polysaccharides consisting of glucose units linked together with β-(1→3)- glycoside bonds. They are principal components of the fungal cell wall including such dangerous nosocomial pathogens as Candida albicans, Aspergillus fumigatus and others. At the same time, β-(1→3) glucans are absent in humans and other mammals, thus making them to be promising components of carbohydrate-protein conjugate vaccines for prevention and treatment of fungal infections. The CRM197 protein is a non-toxic derivative of diphtheria toxin, which is widely used as a safe carrier for conjugate vaccines. The CRM197 extraction from lysogenic C. diphtheriae cultures is a classic way of its production. An alternative to the classic method is a transgene-driven CRM197 protein expression in E. coli, B. subtilis and Pseudomonas fluorescens. The advantage for using Escherichia coli in this case is that this method is more simple and inexpensive, and allows of producing recombinant CRM197 within short terms employing a non-pathogenic microorganism. The purpose of this study was to investigate antigenic activity in the samples of experimental conjugate vaccines based on synthetic oligosaccharide ligands and CRM197 carrier protein, by means of a competitive ELISA. A double immunization of laboratory Balb/c mice with experimental samples of conjugate vaccines based on oligosaccharide ligands and CRM197 protein caused induction of specific antibodies at high titers. All the samples of oligoglucoside-based conjugate vaccines with different contents of monomeric units (pentasaccharides, heptasaccharides, nanosaccharides, and undecasaccharides) caused the formation high antibody titer at the level 1: 51,200,following tandem injections. High avidity of antibodies to their oligosaccharide ligands was shown by competitive ELISA reaction. These data suggest a relevance of further pre-clinical trials of conjugate vaccines against Candida and Aspergillus, as well as selection of the most immunogenic and effective version of the conjugate vaccine.E. G. BogomolovaO. A. DodrovolskayaE. A. FedorovaA. M. KondrashkinaN. N. KolmakovS. A. IshchukI. V. DukhovlinovA. S. SimbirtsevSPb RAACIarticleconjugate vaccinesrecombinant crm197antigenic activitybalb/c miceImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 19, Iss 2, Pp 157-164 (2017)
institution	DOAJ
collection	DOAJ
language	RU
topic	conjugate vaccines recombinant crm197 antigenic activity balb/c mice Immunologic diseases. Allergy RC581-607
spellingShingle	conjugate vaccines recombinant crm197 antigenic activity balb/c mice Immunologic diseases. Allergy RC581-607 E. G. Bogomolova O. A. Dodrovolskaya E. A. Fedorova A. M. Kondrashkina N. N. Kolmakov S. A. Ishchuk I. V. Dukhovlinov A. S. Simbirtsev ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
description	So far, there is no effective treatment for a number of socially significant bacterial and fungal diseases. β-(1→3) glucans are polysaccharides consisting of glucose units linked together with β-(1→3)- glycoside bonds. They are principal components of the fungal cell wall including such dangerous nosocomial pathogens as Candida albicans, Aspergillus fumigatus and others. At the same time, β-(1→3) glucans are absent in humans and other mammals, thus making them to be promising components of carbohydrate-protein conjugate vaccines for prevention and treatment of fungal infections. The CRM197 protein is a non-toxic derivative of diphtheria toxin, which is widely used as a safe carrier for conjugate vaccines. The CRM197 extraction from lysogenic C. diphtheriae cultures is a classic way of its production. An alternative to the classic method is a transgene-driven CRM197 protein expression in E. coli, B. subtilis and Pseudomonas fluorescens. The advantage for using Escherichia coli in this case is that this method is more simple and inexpensive, and allows of producing recombinant CRM197 within short terms employing a non-pathogenic microorganism. The purpose of this study was to investigate antigenic activity in the samples of experimental conjugate vaccines based on synthetic oligosaccharide ligands and CRM197 carrier protein, by means of a competitive ELISA. A double immunization of laboratory Balb/c mice with experimental samples of conjugate vaccines based on oligosaccharide ligands and CRM197 protein caused induction of specific antibodies at high titers. All the samples of oligoglucoside-based conjugate vaccines with different contents of monomeric units (pentasaccharides, heptasaccharides, nanosaccharides, and undecasaccharides) caused the formation high antibody titer at the level 1: 51,200,following tandem injections. High avidity of antibodies to their oligosaccharide ligands was shown by competitive ELISA reaction. These data suggest a relevance of further pre-clinical trials of conjugate vaccines against Candida and Aspergillus, as well as selection of the most immunogenic and effective version of the conjugate vaccine.
format	article
author	E. G. Bogomolova O. A. Dodrovolskaya E. A. Fedorova A. M. Kondrashkina N. N. Kolmakov S. A. Ishchuk I. V. Dukhovlinov A. S. Simbirtsev
author_facet	E. G. Bogomolova O. A. Dodrovolskaya E. A. Fedorova A. M. Kondrashkina N. N. Kolmakov S. A. Ishchuk I. V. Dukhovlinov A. S. Simbirtsev
author_sort	E. G. Bogomolova
title	ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
title_short	ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
title_full	ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
title_fullStr	ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
title_full_unstemmed	ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN
title_sort	antigenic activity assays of experimental conjugate vaccines based on synthetic oligosaccharide ligands and crm197 carrier protein
publisher	SPb RAACI
publishDate	2017
url	https://doaj.org/article/f8febc2e283845ccb8de097f0d48d2b1
work_keys_str_mv	AT egbogomolova antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT oadodrovolskaya antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT eafedorova antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT amkondrashkina antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT nnkolmakov antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT saishchuk antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT ivdukhovlinov antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein AT assimbirtsev antigenicactivityassaysofexperimentalconjugatevaccinesbasedonsyntheticoligosaccharideligandsandcrm197carrierprotein
_version_	1718422392069423104

ANTIGENIC ACTIVITY ASSAYS OF EXPERIMENTAL CONJUGATE VACCINES BASED ON SYNTHETIC OLIGOSACCHARIDE LIGANDS AND CRM197 CARRIER PROTEIN

Ejemplares similares